The FDA approves Perrigo's generic version of AbbVie's (NYSE:ABBV +0.4%) Androgel Topical Gel, 1.62% packets (20.25 mg/1.25 g packet and 40.5 mg/2.5 g packet) for testosterone replacement therapy.

The AndroGel ® (testosterone gel) brand and generic had U.S. sales of approximately $815.6 million MAT for the most recent twelve months ending in February 2019 according to IQVIA Health*.

ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear ...

Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie’s AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions ...

Lupin's testosterone gel, 1.62 percent (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62 percent, Lupin said in a BSE filing. Quoting IQVIA MAT December ...